Cargando…

Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy

Protein losing enteropathy (PLE) refers to excessive intestinal protein loss, resulting in hypoalbuminemia. Underlying pathologies include conditions leading to either reduced intestinal barrier or lymphatic congestion. We describe the case of a patient with long-lasting diffuse abdominal problems a...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanek, Nadine, Bauerfeind, Peter, Herzog, Guido, Heinrich, Henriette, Sauter, Matthias, Lenggenhager, Daniela, Reiner, Cäcilia, Manz, Markus G., Goede, Jeroen S., Misselwitz, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116352/
https://www.ncbi.nlm.nih.gov/pubmed/27891267
http://dx.doi.org/10.1155/2016/9351408
_version_ 1782468651835719680
author Stanek, Nadine
Bauerfeind, Peter
Herzog, Guido
Heinrich, Henriette
Sauter, Matthias
Lenggenhager, Daniela
Reiner, Cäcilia
Manz, Markus G.
Goede, Jeroen S.
Misselwitz, Benjamin
author_facet Stanek, Nadine
Bauerfeind, Peter
Herzog, Guido
Heinrich, Henriette
Sauter, Matthias
Lenggenhager, Daniela
Reiner, Cäcilia
Manz, Markus G.
Goede, Jeroen S.
Misselwitz, Benjamin
author_sort Stanek, Nadine
collection PubMed
description Protein losing enteropathy (PLE) refers to excessive intestinal protein loss, resulting in hypoalbuminemia. Underlying pathologies include conditions leading to either reduced intestinal barrier or lymphatic congestion. We describe the case of a patient with long-lasting diffuse abdominal problems and PLE. Repetitive endoscopies were normal with only minimal lymphangiectasia in biopsies. Further evaluations revealed an indolent marginal zone lymphoma with minor bone marrow infiltration. Monotherapy with rituximab decreased bone marrow infiltration of the lymphoma but did not relieve PLE. Additional treatments with steroids, octreotide, a diet devoid of long-chain fatty-acids, and parenteral nutrition did not prevent further clinical deterioration with marked weight loss (23 kg), further reduction in albumin concentrations (nadir 8 g/L), and a pronounced drop in performance status. Finally, immunochemotherapy with rituximab and bendamustine resulted in hematological remission and remarkable clinical improvement. 18 months after therapy the patient remains free of gastrointestinal complaints and has regained his body weight with normal albumin levels. We demonstrate a case of PLE secondary to indolent marginal zone lymphoma. No intestinal pathologies were detected, contrasting a severe and almost lethal clinical course. Immunochemotherapy relieved lymphoma and PLE, suggesting that a high suspicion of lymphoma is warranted in otherwise unexplained cases of PLE.
format Online
Article
Text
id pubmed-5116352
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-51163522016-11-27 Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy Stanek, Nadine Bauerfeind, Peter Herzog, Guido Heinrich, Henriette Sauter, Matthias Lenggenhager, Daniela Reiner, Cäcilia Manz, Markus G. Goede, Jeroen S. Misselwitz, Benjamin Case Rep Hematol Case Report Protein losing enteropathy (PLE) refers to excessive intestinal protein loss, resulting in hypoalbuminemia. Underlying pathologies include conditions leading to either reduced intestinal barrier or lymphatic congestion. We describe the case of a patient with long-lasting diffuse abdominal problems and PLE. Repetitive endoscopies were normal with only minimal lymphangiectasia in biopsies. Further evaluations revealed an indolent marginal zone lymphoma with minor bone marrow infiltration. Monotherapy with rituximab decreased bone marrow infiltration of the lymphoma but did not relieve PLE. Additional treatments with steroids, octreotide, a diet devoid of long-chain fatty-acids, and parenteral nutrition did not prevent further clinical deterioration with marked weight loss (23 kg), further reduction in albumin concentrations (nadir 8 g/L), and a pronounced drop in performance status. Finally, immunochemotherapy with rituximab and bendamustine resulted in hematological remission and remarkable clinical improvement. 18 months after therapy the patient remains free of gastrointestinal complaints and has regained his body weight with normal albumin levels. We demonstrate a case of PLE secondary to indolent marginal zone lymphoma. No intestinal pathologies were detected, contrasting a severe and almost lethal clinical course. Immunochemotherapy relieved lymphoma and PLE, suggesting that a high suspicion of lymphoma is warranted in otherwise unexplained cases of PLE. Hindawi Publishing Corporation 2016 2016-11-09 /pmc/articles/PMC5116352/ /pubmed/27891267 http://dx.doi.org/10.1155/2016/9351408 Text en Copyright © 2016 Nadine Stanek et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Stanek, Nadine
Bauerfeind, Peter
Herzog, Guido
Heinrich, Henriette
Sauter, Matthias
Lenggenhager, Daniela
Reiner, Cäcilia
Manz, Markus G.
Goede, Jeroen S.
Misselwitz, Benjamin
Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy
title Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy
title_full Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy
title_fullStr Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy
title_full_unstemmed Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy
title_short Marginal Zone Lymphoma Complicated by Protein Losing Enteropathy
title_sort marginal zone lymphoma complicated by protein losing enteropathy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116352/
https://www.ncbi.nlm.nih.gov/pubmed/27891267
http://dx.doi.org/10.1155/2016/9351408
work_keys_str_mv AT staneknadine marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT bauerfeindpeter marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT herzogguido marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT heinrichhenriette marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT sautermatthias marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT lenggenhagerdaniela marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT reinercacilia marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT manzmarkusg marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT goedejeroens marginalzonelymphomacomplicatedbyproteinlosingenteropathy
AT misselwitzbenjamin marginalzonelymphomacomplicatedbyproteinlosingenteropathy